Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus DOXYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus DOXYCHEL.
ACTICLATE CAP vs DOXYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic